Liraglutide (LRT) (AA 7-37) Peptide
-
- Target
- Liraglutide (LRT)
- Protein Region
- AA 7-37
- Source
- Synthetic
- Supplier Product No.
- 000-001-m40
- Supplier
- Rockland
- Purpose
- Liraglutide (GLP 7-37,pal) peptide
- Purity
- Greater than 95% specific peptide.
-
- Application Notes
-
Other: Control peptide should be used at 1.0 μg per 1.0 μL of antiserum per assay.
Application_Note: Liraglutide (GLP 7-37,pal) Control Peptide is suitable for use in ELISA, Western Blot, Dot blot, PCA, and other assays. Control peptide should be used at 1.0 μg per 1.0 μL of antiserum in per assay. Specific conditions for reactivity should be optimized by the end user.
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
-
Reconstitution_Buffer: Restore with deionized water (or equivalent)
Reconstitution_Volume: 1.0 mL
- Concentration
- 1.0 mg/mL
- Preservative
- Without preservative
- Storage
- 4 °C,-20 °C
- Storage Comment
- Store vial at 2 - 8 ° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. Dilute only prior to immediate use.
- Expiry Date
- 12 months
-
- Target
- Liraglutide (LRT)
- Background
-
Synonyms: control peptide, blocking peptide, acylated glucagon-like peptide-1, diabetes research peptide, GLP-1 analogue
Background: Liraglutide is a human glucagon-like peptide-1 (GLP-1) agonist. GLP-1 (7-37) activates the GLP-1 cell-surface membrane-bound receptor in pancreatic beta cells. Liraglutide regulates insulin and glucagon secretions.
-
